Psoriatic arthritis

      PsA asso w/ higher risk of preterm births in women

      Scandinavian registries
      688 PsA pregnancies

      8% preterm births vs.

      Aurelie Najm AurelieRheumo

      4 months 2 weeks ago
      PsA asso w/ higher risk of preterm births in women Scandinavian registries 688 PsA pregnancies 8% preterm births vs. 4.5% general population OR 1.8 16.4% if bDMARD combination OR 4 3.1% if bDMARD monotherapy OR 0.7 bDMARDs combo probably a surrogate of high disease activity
      What's the difference between PIPsA & NIPsA?

      (Persistent Inflammatory confirmed by IMAGING
      vs. Non inflammatory Ps

      Nelly ZIADE 🍀 Nellziade

      4 months 2 weeks ago
      What's the difference between PIPsA & NIPsA? (Persistent Inflammatory confirmed by IMAGING vs. Non inflammatory PsA) 🔹️Cross-sectional study 🔹️517 pts under b/tsDMARDs 🔹️10.3% D2T 🔹️57% PIPsA / 43% NIPsA 👇 Distinct phenotypes 👇 OP0176 #EULAR2025 @rheumnow https://t.co/YGHpbeE6ws
      What happens to the prevalence of D2T PsA if we use different parameters in its definition?

      Data from 5 Nordic registri

      Nelly ZIADE 🍀 Nellziade

      4 months 2 weeks ago
      What happens to the prevalence of D2T PsA if we use different parameters in its definition? Data from 5 Nordic registries including 13,872 patients showed a variation from 37% (less stringent) to 0.6% (more stringent)! OP0177 #EULAR2025 @rheumnow https://t.co/QbF15t3Zrz
      🚨Diagnostic delays are real in axSpA:
      -Can lead to more extra-msk manfieststions (EMMs) in PsA and axSpA.
      -Increases

      Adela Castro AdelaCastro222

      4 months 2 weeks ago
      🚨Diagnostic delays are real in axSpA: -Can lead to more extra-msk manfieststions (EMMs) in PsA and axSpA. -Increases disease burden and productivity losses. -EMMs can present before articular sx -Uveitis and IBD associated with longer dx delays. -Diagnosis has improved since https://t.co/rWMwG7Ewwe
      A machine learning (ML) model using electronic medical record (EMR) data from 396,000 Mayo Clinic primary care patients

      Antoni Chan MD (Prof) synovialjoints

      4 months 2 weeks ago
      A machine learning (ML) model using electronic medical record (EMR) data from 396,000 Mayo Clinic primary care patients identified undiagnosed psoriatic arthritis (PsA) with area under the curve (AUC) 79.6%. Key predictors: psoriasis, joint pain, tenosynovitis, https://t.co/VsYevnJEjK
      In 1314 PsA patients, cumulative methotrexate dose was not associated with liver fibrosis (OR 0.99). Instead, higher BMI

      Antoni Chan MD (Prof) synovialjoints

      4 months 2 weeks ago
      In 1314 PsA patients, cumulative methotrexate dose was not associated with liver fibrosis (OR 0.99). Instead, higher BMI (OR 1.03) & diabetes (OR 5.03) were key drivers. MASLD, not MTX, may underlie fibrosis risk in PsA. APRI >0.7 used for fibrosis detection. Abstract#POS0111 https://t.co/zsX7NUOT9m
      Deucravacitinib's Place in the PsA Treatment Algorithm?
      4 months 2 weeks ago
      Tofacitinib vs biologics in PsA:
      📍MI/stroke ✅ similar
      📍Serious infection ✅ similar
      📍Malignancy ✅ similar

      Jiha Lee JihaRheum

      4 months 2 weeks ago
      Tofacitinib vs biologics in PsA: 📍MI/stroke ✅ similar 📍Serious infection ✅ similar 📍Malignancy ✅ similar 📍VTE ❌ higher vs TNFi (aHR 0.26) Large US claims study (n=48k) Abstract POS0296 @RheumNow #EULAR2025
      📊 SIJ findings in PsA (n=581):
      🧠 31% = MRI-confirmed axSpA
      🦴 Only 29% met r-mNY criteria
      MRI-axPsA group: young

      Jiha Lee JihaRheum

      4 months 2 weeks ago
      📊 SIJ findings in PsA (n=581): 🧠 31% = MRI-confirmed axSpA 🦴 Only 29% met r-mNY criteria MRI-axPsA group: younger, more male, HLA-B27+ Clinical + radiographic definitely underperform vs MRI #POS0297 @RheumNow #EULAR2025
      PsO + recent arthralgia—but no PsA. Treat or wait?
      🧠 18% developed PsA in 3 yrs, most in year 1
      🔍 Predictors: te

      Jiha Lee JihaRheum

      4 months 2 weeks ago
      PsO + recent arthralgia—but no PsA. Treat or wait? 🧠 18% developed PsA in 3 yrs, most in year 1 🔍 Predictors: tender joints, disability, enthesis erosion Consider early rheum input for these patients Abstract POS0299 @RheumNow #EULAR2025
      Can RZB deliver in real-world early PsA?
      💥 9-month results say yes:
      ✅ Dactylitis gone in 79%
      ✅ Enthesitis in 90%

      Jiha Lee JihaRheum

      4 months 2 weeks ago
      Can RZB deliver in real-world early PsA? 💥 9-month results say yes: ✅ Dactylitis gone in 79% ✅ Enthesitis in 90% ✅ 97% MDs & 88% pts satisfied Early intervention may pay off. Abstract POS0304 @RheumNow #EULAR2025
      #Psoriatic_Arthritis
      #Preclinical #Early

      ❓️ Does joint swelling occur in the same anatomical locations affected in

      Nelly ZIADE 🍀 Nellziade

      4 months 2 weeks ago
      #Psoriatic_Arthritis #Preclinical #Early ❓️ Does joint swelling occur in the same anatomical locations affected in the subclinical phase? 🅰️ Yes, in 68% 🅰️ Especially if positive ultrasound #EULAR2025 @RheumNow OP0179 by Ivan Giivannini et al. https://t.co/rKfreQyJeG
      Acute Dactylitis in #Psoriatic_Arthritis

      🔹️1216 patients Canada 🇨🇦
      🔹️52% had at least one episode of a

      Nelly ZIADE 🍀 Nellziade

      4 months 2 weeks ago
      Acute Dactylitis in #Psoriatic_Arthritis 🔹️1216 patients Canada 🇨🇦 🔹️52% had at least one episode of acute dactylitis in a median 12 years 🔹️Positive association with HLA-B27 and HLA-B27/C02 🔹️No association with HLA-B51 #EULAR2025 @RheumNow OP0180 by Kharouf et al. https://t.co/oNNMBcvVb4
      In PsA, can we better pick IL-17A inhibitor responders (after TNFi failure)?

      Transcriptomic profiling is going to get b

      David Liew drdavidliew

      4 months 2 weeks ago
      In PsA, can we better pick IL-17A inhibitor responders (after TNFi failure)? Transcriptomic profiling is going to get better at telling us which pathways are truly important for response to specific treatments POS0232 #EULAR2025 @RheumNow https://t.co/uycuXB0TFK
      IL17
      Expanding the IL-17 Therapeutic Landscape
      4 months 2 weeks ago
      IL-17 inhibitors are an effective therapeutic for a broad spectrum of inflammatory and autoimmune diseases and its blockade has revolutionized management of diseases such as psoriasis, psoriatic arthritis and SpA. Is there a need for more medications within the same therapeutic class?

      Catch up on Conference Podcasts

      ×